Nuvectis Pharma (NVCT) Operating Expenses (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Operating Expenses data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 12.43% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $28.3 million (up 34.48% YoY), and the FY2025 full-year result was $28.0 million, up 38.74% from the prior year.
• Operating Expenses fell to $6.3 million in Q1 2026, from $7.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $7.8 million in Q3 2025 to a low of $2.0 million in Q1 2022.
• A 5-year average of $5.6 million and a median of $5.9 million in 2022 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 199.25% in 2022, while the deepest fall reached 39.83% in 2022.
• Tracing NVCT's Operating Expenses over 5 years: stood at $6.8 million in 2022, then rose by 1.3% to $6.9 million in 2023, then retreated by 6.07% to $6.4 million in 2024, then rose by 18.11% to $7.6 million in 2025, then fell by 17.82% to $6.3 million in 2026.
• Business Quant data shows NVCT's Operating Expenses at $6.3 million in Q1 2026, $7.6 million in Q4 2025, and $7.8 million in Q3 2025.